ESR1 and breast carcinoma: Contrasting IGHA2 mRNA, IGHG1 was associated with features linked to poor prognosis, such as ER negativity, HER2 amplification, and higher grade, which is in line with what has been reported for B-lymphocytes in breast cancer tissue7.